What type of study is this?

September 5, 2025Open Access

Supplementary Figure S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

View Full Paper

Ask AI

Bookmark

HBS-101 effectively induces apoptosis in MDA-MB-231 and BT-549 cells via midkine inhibition.
Flow cytometry confirmed increased Annexin V staining, marking apoptotic cell death post-treatment with HBS-101.
Analysis was performed with established breast cancer cell lines, providing insights into potential therapeutic applications.
The findings highlight the need for further investigation into HBS-101's efficacy as a treatment for triple-negative breast cancer.

Implication

Supplementary findings show HBS-101 induces apoptosis in MDA-MB-231 and BT-549 cells, implying therapeutic potential.

Abstract

Supplementary Figure S4: A-B, MDA-MB-231 (A), and BT-549 (B), cells were treated with HBS-101, stained with Annexin V, and analyzed by flow cytometry. Scatter plots illustrate Annexin V staining in control and HBS-101-treated cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mahajan et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd0289a https://doi.org/10.1158/1535-7163.30028855

View Full Paper

Ask AI

Bookmark

Implication

Supplementary findings show HBS-101 induces apoptosis in MDA-MB-231 and BT-549 cells, implying therapeutic potential.

Supplementary Figure S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading